Norton Thoracic Institute, St Joseph's Hospital and Medical Center, Phoenix, Ariz; Creighton University School of Medicine-Phoenix Regional Campus, Phoenix, Ariz.
Norton Thoracic Institute, St Joseph's Hospital and Medical Center, Phoenix, Ariz; Creighton University School of Medicine-Phoenix Regional Campus, Phoenix, Ariz.
J Thorac Cardiovasc Surg. 2020 Dec;160(6):1613-1626. doi: 10.1016/j.jtcvs.2019.12.120. Epub 2020 Feb 19.
Esophageal aperistalsis has been considered a relative contraindication for lung transplant because of a higher risk of allograft dysfunction secondary to reflux and aspiration induced by poor esophageal clearance. We previously reported that esophageal motility improves in some patients after lung transplant. We reviewed the clinical course of lung transplant recipients diagnosed with an aperistaltic esophagus on pretransplant testing.
We identified patients diagnosed with pretransplant aperistaltic esophagus on high-resolution manometry who underwent lung transplant. Recipients with normal esophageal motility before lung transplant were used as the propensity score-matched control group. High-resolution manometry was repeated after lung transplant, and patients with aperistalsis were further divided into 2 subgroups: improved esophageal peristalsis and nonimproved peristalsis (ie, persistent aperistalsis after lung transplant).
Esophageal aperistalsis was seen in 31 patients (mean age, 59.0 years; 21 men). The 1-, 3-, and 5-year post-lung transplant survivals in the aperistalsis group were 80.6%, 51.2%, and 34.9%, respectively, which was significantly lower than in the control group (90.3%, 73.4%, and 58.8%, respectively; P = .038). Post-lung transplant high-resolution manometry was performed for 29 patients in the aperistalsis group, 19 of whom demonstrated improved esophageal motility (65.5%). The 1-, 3-, and 5-year survivals after lung transplant of patients with recovery of peristalsis were similar to those of the control group (89.5%, 65.0%, and 48.8%, respectively; P = 1.000), whereas the nonimproved peristalsis group had lower survival (80.0%, 36.0%, and data unavailable, respectively; P = .012).
Esophageal aperistalsis is not necessarily a contraindication for lung transplant. Improved peristalsis can be expected in up to two-thirds of these patients and is associated with good outcomes.
由于食管清除能力差导致的反流和误吸会使移植物功能障碍的风险增加,因此食管蠕动功能障碍被认为是肺移植的相对禁忌证。我们之前曾报道过,一些肺移植患者的食管蠕动功能在移植后会得到改善。我们回顾了在移植前检查中被诊断为食管无蠕动的肺移植受者的临床过程。
我们确定了在高分辨率测压检查中被诊断为移植前食管无蠕动的患者,并对其进行了肺移植。将肺移植前食管蠕动正常的患者作为倾向评分匹配的对照组。在肺移植后重复进行高分辨率测压检查,将食管无蠕动的患者进一步分为 2 个亚组:食管蠕动改善和无蠕动改善(即肺移植后仍存在食管无蠕动)。
31 例患者(平均年龄 59.0 岁,21 例男性)被诊断为食管无蠕动。无蠕动组的 1、3 和 5 年肺移植存活率分别为 80.6%、51.2%和 34.9%,显著低于对照组(90.3%、73.4%和 58.8%;P=.038)。在无蠕动组中,有 29 例患者在肺移植后进行了高分辨率测压检查,其中 19 例患者的食管蠕动得到改善(65.5%)。恢复蠕动的患者的 1、3 和 5 年肺移植存活率与对照组相似(分别为 89.5%、65.0%和 48.8%;P=1.000),而无蠕动改善组的存活率较低(分别为 80.0%、36.0%和数据不可用;P=.012)。
食管无蠕动不一定是肺移植的禁忌证。这些患者中有多达三分之二的患者可以预期出现蠕动改善,并且预后良好。